Application of molecular marker SBDS as detection target in preparation of diagnosis, screening and prognosis evaluation product species
Through the molecular marker SBDS and its expression products, the problem of ineffective diagnosis markers of hepatocellular carcinoma in the prior art is solved, and more accurate early screening and diagnosis methods for liver cancer are provided, which improves diagnostic accuracy and prognosis evaluation, and enhances the Understanding of the behavior of liver cancer cells.
Patent Information
- Application Number
- CN202411335425.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-24
- Publication Date
- 2024-12-03
AI Technical Summary
Existing hepatocellular carcinoma (HCC) diagnostic markers such as alpha-fetoprotein (AFP) are ineffective in 30% of patients, resulting in increased diagnosis difficulty, and the accuracy of other protein markers is insufficient to meet the early diagnosis needs, resulting in the onset of liver cancer. Rates and mortality continue to rise.
Using the molecular marker SBDS and its expression products as prediction and identification markers for liver cancer, specific primers and probes are provided through nucleotide sequences for the preparation of diagnostic, screening and prognosis evaluation products, combining kits and PCR reaction technology Perform testing.
Through the detection of expression level of SBDS molecular markers, the accuracy of early screening and diagnostic accuracy of liver cancer is improved, the diagnostic process is simplified, and new prognostic evaluation indicators are provided, which enhances the ability of liver cancer cells to proliferate, migrate and invade liver cancer cells. understand.
Smart Images

Figure CN119061145A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of molecular biology, and in particular to the application of a molecular marker SBDS as a detection target in the preparation of diagnosis, screening and prognosis evaluation products. Background Art
[0002] Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer (PLC). HBV infection, HCV infection, excessive alcoholism, smoking and aflatoxin infection are the most common high-risk factors for HCC. So far, the incidence of HCC is still increasing worldwide, becoming one of the common malignant tumors that endanger human health. At present, surgical operations are the main treatment, combined with multidisciplinary diagnosis and treatment models such as targeted, immune, interventional, radiotherapy, chemotherapy, and traditional Chinese medicine, which have made great progress in the treatment of HCC. However, despite this, the 5-year relative survival rate of patients calculated after combining all stages of HCC is about 18%, which is still the lowest among all malignant tumors. The clinical prognosis of HCC patients is still poor, which is ultimately due to its malignant phenotypes such as insidious onset, rapid progression, and easy metastasis. Therefore, it is necessary to find new prognostic factors and potential molecular mechanisms to improve the prevention and treatment of HCC.
[0003] Over the past 40 years, alpha-fetoprotein (AFP), as a unique HCC-specific serum marker, has been widely used in the detection, diagnosis, evaluation of treatment effects, and prediction of recurrence of HCC, and has played an important role. However, 30% of HCC patients do not show elevated AFP, and sometimes it may even be negative, which increases the difficulty of HCC diagnosis. So far, many protein markers, such as AFPL3, IL6, and PIVKA-II, have also been tested to varying degrees. However, their accuracy cannot meet people's expectations for early diagnosis of HCC. According to the 2018 global cancer statistics, there were 841,080 new cases and 781,631 deaths from liver cancer reported. In addition, according to the cancer statistics in the United States in 2020, the incidence of liver cancer has been snowballing compared with other types of cancer. Therefore, it is of great significance to find new HCC-specific tumor markers. Summary of the invention
[0004] The purpose of the present invention is to solve the above problems and provide a molecular marker SBDS for hepatocellular carcinoma and its application. The SBDS and its expression products can be used as molecular markers to predict the occurrence of liver cancer and identify the type of liver cancer, thus providing new ideas for the early clinical prevention and treatment of liver cancer.
[0005] In order to achieve the above object, the technical solution of the present invention is as follows:
[0006] The molecular marker SBDS is used as a detection target in any of the following applications:
[0007] S1. Use in the preparation of products for diagnosis or auxiliary diagnosis of hepatocellular carcinoma;
[0008] S2. Use in the preparation of products for screening or auxiliary screening of hepatocellular carcinoma;
[0009] S3. Use in the preparation of a product for the prognosis assessment of hepatocellular carcinoma;
[0010] The nucleotide sequence of the molecular marker SBDS is shown in SEQ ID No.1.
[0011] The nucleotide sequence shown in SEQ ID No.1 is as follows:
[0012] atgtcgatcttcaccccccaccaaccagatccgcctaaccaatgtggccgtggtacggatgaagcgtgccgggaagcgcttcgaaatcgcctgctacaaaaacaaggtcgtcggctggcggagcggcgtggaaaagacctcgatg aagttctgcagacccatcagtgtttgtaaatgtttctaaaggtcaggttgccaaaaaggaagatctcatcagtgcgtttggaacagatgaccaaactgaaatctgtaagcagattttgactaaaggagaagttcaagtatcagat aaagaaagacacacacaactggagcagatgtttagggacattgcaactattgtggcagacaaatgtgtgaatcctgaaacaaagagaccatacaccgtgatccttattgagagagccatgaaggacatccactattcggtgaaaa ccaacaagagtacaaaacagcaggctttggaagtgataaagcagttaaaagagaaaatgaagatagaacgtgctcacatgaggcttcggttcatccttccagtcaatgaaggcaagaagctgaaagaaaagctcaagccactgat caaggtcatagaaagtgaag attatggccaacagttagaa atcgtatgtc tgattgaccc gggctgcttccgagaaattgatgagctaataaaaaaggaa actaaaggca aaggttcttt ggaagtactc aatctgaaagatgtagaagaaggagatgagaaatttgaat ga.
[0013] The material for detecting the molecular marker SBDS is used in any of the following applications:
[0014] S1. Use in the preparation of products for diagnosis or auxiliary diagnosis of hepatocellular carcinoma;
[0015] S2. Use in the preparation of products for screening or auxiliary screening of hepatocellular carcinoma;
[0016] S3. Use in the preparation of a product for the prognosis assessment of hepatocellular carcinoma;
[0017] The nucleotide sequence of the molecular marker SBDS is shown in SEQ ID No.1.
[0018] Furthermore, the substance includes primers for specifically amplifying the molecular marker SBDS, probes for specifically recognizing the molecular marker SBDS and / or binding agents for specifically binding to the molecular marker SBDS.
[0019] Further, the primer is a primer pair, the primer pair includes an upstream primer and a downstream primer, the upstream primer is a single-stranded DNA with a nucleotide sequence of SEQ ID No. 2, and the downstream primer is a single-stranded DNA with a nucleotide sequence of SEQ ID No. 3. Specifically, the nucleotide sequence of the upstream primer SEQ ID No. 2 is: 5'-TGAAGTTCTGCAGACCCACTC-3'. The nucleotide sequence of the upstream primer SEQ ID No. 3 is: 5'-GCTTACAGATTTCAGTTTGGTCAT-3'.
[0020] Another object of the present invention is to provide a primer pair.
[0021] Primer pairs as described above.
[0022] The primer pair as mentioned above is used in preparing products for detecting the molecular marker SBDS.
[0023] A kit comprises the above-mentioned substance for detecting the molecular marker SBDS, and the kit is used for detecting the molecular marker SBDS or for diagnosis, auxiliary diagnosis, screening, auxiliary screening or prognosis evaluation of hepatocellular carcinoma.
[0024] Preferably, the kit comprises reverse transcriptase, buffer, water, amplification primers, DNA polymerase, and dNTPs.
[0025] A method for detecting the molecular marker SBDS comprises using the above primer pair or the above kit to detect a sample to be detected.
[0026] The method comprises the following steps:
[0027] A. Extract RNA from the sample to be tested;
[0028] B. reverse transcribing the RNA into cDNA;
[0029] C. Using the cDNA as a template, a PCR reaction is performed using the primer pair described in claim 5.
[0030] Furthermore, the samples to be tested are liver cancer tissue and peripheral blood.
[0031] Any of the following uses of an agent or drug for overexpressing the molecular marker SBDS:
[0032] I. Use in the preparation of a drug for inhibiting the migration or metastasis of hepatocellular carcinoma cells;
[0033] II. Application in the preparation of drugs for treating or preventing hepatocellular carcinoma.
[0034] SBDS is named because its mutation is highly correlated with Shwachman-Bodian Diamond syndrome (SBDS). The main characteristics of this syndrome are pancreatic dysfunction, circulatory system failure, skeletal deformities and nervous system-related phenotypes. Previous studies have found that SBDS plays an important role in embryonic development. It can participate in the synthesis of ribosomal RNA (rRNA) and the maturation of ribosomes, but the role of SBDS in cancer is still unclear. Hao et al. found that SBDS is often overexpressed in human cancers, and the high expression level of endogenous SBDS is significantly associated with the poor prognosis of patients. On the contrary, knocking down SBDS can mediate the stabilization and activation of p53 through the ribosome stress-RPL5 / RPL11-MDM2 signaling pathway, thereby inhibiting the proliferation and invasion of cancer cells. However, there is no research on the relationship between SBDS and hepatocellular carcinoma.
[0035] It is worth noting that in vitro and in vivo experiments have found that abnormal localization of SBDS in the cell nucleus can also inhibit the growth and proliferation of tumor cells. Mechanistic studies have confirmed that ectopic expression of SBDS is triggered by ribosome stress, which binds to the transactivation domain of p53, inhibits the interaction between p53 and MDM2, and thus interferes with the ubiquitination and degradation of p53. The above experiments, through the coordinated study of ribosome synthesis and p53 activity, have demonstrated for the first time the dual functions of SBDS in the occurrence and development of cancer.
[0036] In addition, previous studies have shown that SBDS can cause human eukaryotic translation initiation factor 6 (EIF6) to dissociate from the 60S ribosomal subunit in the cytoplasm, enhancing the translocation of EIF6 into the nucleus, thereby participating in the formation and development of ribosomes. Impaired ribosome biogenesis can induce ribosome stress, inhibit the ubiquitination and degradation of p53, and then lead to the accumulation of p53 in cells and mediate cell apoptosis. Among them, EIF6 is a conserved protein present in eukaryotes. It was discovered in mammals more than 30 years ago, and recent studies have shown that it is one of the EIFs that play a role in controlling protein synthesis. Most of EIF6 is present in the cytoplasm of eukaryotic cells, while the nucleus contains a smaller amount (~30%) but an essential part. It has been reported that EIF6, as a dual factor, not only promotes the biogenesis of 60S ribosomes in the nucleolus, but also prevents the assembly of 40S and 60S ribosomal subunits in the cytoplasm, so subcellular localization may be crucial for the functional regulation of EIF6. In addition, recent studies have confirmed that EIF6 is dysregulated in a variety of cancers, such as liver cancer, colorectal carcinoma (CRC), malignant pleural mesothelioma (MPM), ovarian serous carcinoma (OV), breast cancer (MBC), non-small cell lung cancer (NSCLC) and gallbladder cancer (GBC).
[0037] There are also studies reporting that in HCC, the interaction between FCN3 and SBDS reduces the cytoplasmic-nuclear translocation of EIF6 and induces ribosome stress, thereby inhibiting the development of HCC. As a tumor suppressor, P53 is known to maintain genomic stability, inhibit the transformation of epithelial cells to mesenchymal cells, trigger cell apoptosis, and intervene in cancer metabolism to prevent malignant tumors. However, there are no studies on SBDS and hepatocellular carcinoma.
[0038] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:
[0039] The present invention compared the expression differences of SBDS in diseased and non-disease, paired cancer / paracancerous tissues and found that SBDS was significantly upregulated in HCC cancer tissues, and the SBDS expression level in the HCC patient group with vascular invasion was significantly higher than that in the HCC patient group without vascular invasion. The proliferation activity of cells was detected by CCK-8 experiment, and the results showed that overexpression of SBDS could promote the proliferation activity of HepG2 cells; the effect of overexpression of SBDS on the proliferation ability of HepG2 cells was detected by plate clone formation experiment, and it was found that overexpression of SBDS could promote the clone formation ability of HepG2 cells; the effect of overexpression of SBDS on the in vitro migration ability of HepG2 cells was detected by cell scratch healing experiment, and the results showed that overexpression of SBDS could promote the scratch healing ability of liver cancer cell HepG2 cells; the in vitro migration ability of HepG2 cells after overexpression of SBDS was detected by Transwell chamber, and the results showed that the ability of HepG2 cells overexpressing SBDS to penetrate the chamber was enhanced, and SBDS could promote the in vitro migration ability of liver cancer cell HepG2 cells; the in vitro invasion ability of liver cancer cell HepG2 cells after overexpression of SBDS was detected by Transwell chamber, and the results showed that the ability of liver cancer cell HepG2 cells overexpressing SBDS to penetrate the chamber was enhanced, which could enhance the in vitro invasion ability of liver cancer cells. Therefore, the present invention proposes the use of the molecular marker SBDS as a detection target in the preparation of products for diagnosis, screening and prognosis evaluation of hepatocellular carcinoma; provides a kit including a substance for detecting the molecular marker SBDS, provides a more reliable judgment basis for early screening of liver cancer, and can use the objective indicator of the expression level of the SBDS molecular marker to conduct a comprehensive evaluation with other early tumor screening markers, thereby improving the diagnostic accuracy, simplifying the diagnostic process, and playing a significant role in the diagnosis and treatment of liver cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 The figure is a test result diagram comparing the expression difference of SBDS in disease and non-disease and paired cancer / paracancerous tissues in the examples.
[0041] Figure 2 The figure shows the difference test results of SBDS expression levels in HCC patient groups with or without vascular invasion.
[0042] Figure 3 This is a test result diagram of the effect of overexpressed SBDS on the proliferation activity of HepG2 cells detected by CCK-8 reagent.
[0043] Figure 4 This is a test result diagram of the plate clone formation experiment to detect the effect of overexpression of SBDS on the proliferation ability of HepG2 cells.
[0044] Figure 5This is a test result diagram of the cell scratch healing experiment to detect the effect of overexpression of SBDS on the in vitro migration ability of HepG2 cells.
[0045] Figure 6 This is a graph showing the test results of the in vitro migration ability of HepG2 cells after overexpressing SBDS using Transwell chamber.
[0046] Figure 7 This is a graph showing the test results of the in vitro invasion ability of liver cancer cell HepG2 cells overexpressing SBDS using Transwell chamber. DETAILED DESCRIPTION
[0047] The present invention will be described in detail below in conjunction with the accompanying drawings.
[0048] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0049] Example 1
[0050] This example found through bioinformatics analysis that SBDS was significantly upregulated in liver cancer tissues compared with adjacent tissues of liver cancer patients, and was associated with multiple clinical indicators such as distant tumor metastasis and AFP. Further cell and animal experiments verified the first discovery that SBDS can promote the proliferation and metastasis of HCC cells. 1.0
[0052] Download the TCGA-LIHC database and compare the expression differences of SBDS in disease and non-disease and paired cancer / paracancerous tissues. Figure 1 shown.
[0053] The results showed that SBDS was significantly upregulated in HCC tissues, P < 0.05. 2.0
[0055] According to whether HCC patients had vascular invasion, the patients were divided into NO group and YES group, and the difference in SBDS expression levels between the two groups was compared. Figure 2 As shown, the results showed that the expression level of SBDS in the HCC patient group with vascular invasion was significantly higher than that in the HCC patient group without vascular invasion, P < 0.05.
[0056] Effects of 3.0SBDS on the biological behavior of human hepatocellular carcinoma cell line HepG2
[0057] 3.1 CCK-8 assay to detect cell proliferation activity
[0058] CCK-8 reagent was used to detect the effect of overexpression of SBDS on the proliferation activity of HepG2 cells. The cell lines of the HepG2 group and HepG2+OE group were cultured separately, and the absorbance value (OD value) at 450 nm was measured after 12 h, 24 h, 48 h, and 72 h of culture in each group of cells, and the growth curve was drawn. Figure 3 The results showed that after 72 hours of cell culture, the cell viability of the HepG2+OE group was significantly higher than that of the HepG2 group, and the difference was statistically significant (p<0.05), suggesting that overexpression of SBDS can promote the proliferation activity of HepG2 cells.
[0059] 3.2 Plate colony formation experiment
[0060] The effect of overexpression of SBDS on the proliferation ability of HepG2 cells was detected by plate clone formation assay. Figure 4 The results showed that the growth state of the cloned cells was good. Compared with the HepG2 group and the HepG2+NC group, the number of cloned cells in the HepG2+OE group increased significantly, and the difference was statistically significant (p<0.001); while there was no significant statistical difference between the HepG2 group and the HepG2+NC group (p>0.05). The experiment showed that overexpression of SBDS can promote the clonal formation ability of HepG2 cells.
[0061] 3.3 Effect of SBDS overexpression on cell migration ability
[0062] The effect of overexpression of SBDS on the in vitro migration ability of HepG2 cells was detected by cell scratch healing assay. The scratch area was used to represent the in vitro migration ability of the cells, and the scratch area of each group of cells was compared after 24 hours. Figure 5 As shown. The results show that compared with the HepG2 group and the HepG2+NC group, the scratch area of the HepG2+OE group is smaller, and the difference is statistically significant (P<0.001). However, there is no significant statistical difference in the scratch area between the HepG2 group and the HepG2+NC group (p>0.05). The experiment shows that SBDS overexpression can promote the scratch healing ability of liver cancer cell HepG2 cells.
[0063] 3.4 Transwell assay for cell migration
[0064] Transwell chamber was used to detect the in vitro migration ability of HepG2 cells after overexpression of SBDS. DMEM complete medium containing 10% FBS was added to the lower chamber, and the cells of HepG2 group, HepG2+NC group and HepG2+OE group were inoculated into the upper chamber of Transwell, respectively. Figure 6As shown. The results showed that compared with the HepG2 group and the HepG2+NC group, the number of cells penetrating the chamber in the HepG2+OE group increased significantly, and the difference was statistically significant (p<0.05); while there was no significant statistical difference between the HepG2 group and the HepG2+NC group (p>0.05). The experiment showed that the ability of HepG2 cells overexpressing SBDS to penetrate the chamber was enhanced, which was consistent with the results of the cell scratch experiment mentioned above, indicating that SBDS can promote the in vitro migration ability of liver cancer cell HepG2 cells.
[0065] 3.5 Transwell assay for cell invasion ability
[0066] Transwell chamber was used to detect the in vitro invasion ability of HepG2 cells overexpressing SBDS. Complete medium containing 10% FBS was added to the lower chamber, and cells of HepG2 group, HepG2+NC group and HepG2+OE group were inoculated into the upper chamber of the Transwell chamber covered with matrigel in advance, and the number of cells that penetrated the chamber in each group was observed. Figure 7 shown.
[0067] The results showed that compared with the HepG2 group and the HepG2+NC group, the number of cells penetrating the chamber in the HepG2+OE group increased significantly, and the difference was statistically significant (P<0.05), while there was no statistical difference between the HepG2 group and the HepG2+NC group (P>0.05). The experiment showed that the ability of HepG2 cells to penetrate the chamber was enhanced after overexpression of SBDS, which can enhance the in vitro invasion ability of liver cancer cells.
[0068] Example 2
[0069] Primers for SBDS gene amplification were synthesized. The primer sequences and related information are shown in Table 1, including primer sequences, GC content, TM value and other related information.
[0070] Table 1 Primer sequences for real-time fluorescence quantitative PCR
[0071]
[0072] Preparation of total RNA from samples
[0073] (1) The Trizol method was used to extract total RNA from liver cancer tissue and blood. 0.2 g of tissue was taken and ground under liquid nitrogen until it became powder. 1 ml of Trizol was added to the liquid nitrogen and the grinding was continued. After the Trizol was ground into dry powder, it was allowed to stand at room temperature. After the dry powder turned into liquid, all the liquid was collected.
[0074] (2) After the sample liquid was lysed at room temperature for 5 minutes, 0.2 ml of chloroform was added to every 1 ml of Trizol grind homogenate, the tube cap was tightly closed, and vortexed for 15 seconds. After standing for stratification, the mixture was centrifuged at 12000 rpm for 15 minutes at 4°C. After centrifugation, the mixed liquid was separated into a lower phenol chloroform phase, a middle protein layer, and an upper colorless aqueous phase. All RNA was distributed in the aqueous phase.
[0075] (3) Transfer the aqueous phase to a new centrifuge tube, add 0.5 ml of isopropanol to 1 ml of Trizol homogenate, mix manually, let stand at -20°C for 30 min, and centrifuge at 12,000 rpm for 15 min at 4°C to obtain a precipitate. All RNA is present in the precipitate.
[0076] (4) Remove the supernatant, add 1 ml of 75% ethanol to wash the RNA precipitate, and centrifuge at 7500 rpm for 5 minutes at 4°C.
[0077] (5) Remove the ethanol solution and dry at room temperature for 5-10 minutes until the ethanol evaporates (do not allow the RNA to dry completely, as this will reduce its solubility). Add RNase-free deionized water to the centrifuge tube and incubate at 60°C for 5 minutes to obtain total RNA.
[0078] (6) The concentration and purity of the extracted total RNA were measured using NanoDrop ND-2000 to ensure that the concentration and purity of the total RNA could meet the requirements of subsequent experiments. The total RNA solution was stored in a -80°C refrigerator.
[0079] Synthesis of first-strand cDNA sequence (first step of two-step method)
[0080] Take a PCR tube and prepare the reverse transcription system. The reverse transcription system is: 1 μl total RNA (about 500 ng), 1 μl random primers (Thermo), 10 μl ddH2O (Tiangen Biotechnology Co., Ltd.), 2 μl dNTP mixture (dATP, dGTP, dCTP and dTTP, Invitrogen), 4 μl reverse transcription buffer (Thermo), 1 μl RNase inhibitor (Thermo), 1 μl reverse transcriptase (Thermo), and the total volume is 20 μl. The reaction conditions are: 25℃5min; 42℃60min, 70℃5min. Reverse transcription is performed using an ABI PCR amplifier. cDNA is stored at -80℃ for later use.
[0081] LncRNA00892 gene cDNA amplification and verification
[0082] Take 2μl of the cDNA reverse transcribed in step 3 and configure the system for PCR amplification. The PCR amplification system is: 2μl cDNA, 0.5μl upstream specific primer, 0.5μl downstream specific primer, 7μl ddH2O (Tiangen Biotechnology Co., Ltd.), 10μl PCR amplification Mix (TAKARA), and a total volume of 20μl. The reaction conditions are 94℃5min; 35 cycles of 94℃30s, TM℃20s, and 72℃20s; 72℃5min. Take 2μl of the reaction product and verify whether the PCR product is a single specific amplification band under the conditions of 1.5g agarose / 100ml 1×TAE buffer, 120V voltage, and 25min.
[0083] LncRNA00892 gene detection kit (two-step method, step 2)
[0084] The cDNA samples obtained by reverse transcription were used for detection.
[0085] The reaction system was: 2 μl cDNA, 0.8 μl upstream specific primer, 0.8 μl downstream specific primer, 6.4 μl ddH2O (Tiangen Biotechnology Co., Ltd.), 10 μl fluorescent quantitative PCR amplification Mix (SYBGREEN dye), and the total volume was 20 μl.
[0086] Real-time PCR reaction conditions: 95°C pre-denaturation for 5 min, followed by 40 cycles of 98°C for 10 s and 62°C for 30 s. Amplification was performed on a real-time fluorescence quantitative PCR instrument, LightCyler 480.
[0087] While amplifying the target gene, β-actin was amplified as an internal reference, and the relative expression of the gene was calculated by the 2(-△△CT) method.
[0088] This embodiment provides a kit for detecting the molecular marker SBDS or for diagnosis, auxiliary diagnosis, screening, auxiliary screening or prognosis evaluation of hepatocellular carcinoma, including a substance for detecting the molecular marker SBDS, specifically including a primer pair, an upstream primer and a downstream primer, the upstream primer is a single-stranded DNA with a nucleotide sequence of SEQ ID No. 2, and the downstream primer is a single-stranded DNA with a nucleotide sequence of SEQ ID No. 3. Preferably, it also includes reverse transcriptase, buffer, water, DNA polymerase, and dNTP.
[0089] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. The molecular marker SBDS is used as a detection target in any of the following applications: S1. Use in the preparation of products for diagnosis or auxiliary diagnosis of hepatocellular carcinoma; S2. Use in the preparation of products for screening or auxiliary screening of hepatocellular carcinoma; S3. Use in the preparation of a product for the prognosis assessment of hepatocellular carcinoma; The nucleotide sequence of the molecular marker SBDS is shown in SEQ ID No.
1.
2. The substance for detecting the molecular marker SBDS is used in any of the following applications: S1. Use in the preparation of products for diagnosis or auxiliary diagnosis of hepatocellular carcinoma; S2. Use in the preparation of products for screening or auxiliary screening of hepatocellular carcinoma; S3. Use in the preparation of a product for the prognosis assessment of hepatocellular carcinoma; The nucleotide sequence of the molecular marker SBDS is shown in SEQ ID No.
1.
3. The use according to claim 2, characterized in that: The substance includes a primer for specifically amplifying the molecular marker SBDS, a probe for specifically recognizing the molecular marker SBDS and / or a binding agent for specifically binding to the molecular marker SBDS.
4. The use according to claim 3, characterized in that: The primers are a primer pair, which includes an upstream primer and a downstream primer. The upstream primer is a single-stranded DNA whose nucleotide sequence is SEQ ID No.2, and the downstream primer is a single-stranded DNA whose nucleotide sequence is SEQ ID No.
3.
5. The primer pair according to claim 4.
6. Use of the primer pair as claimed in claim 4 in preparing a product for detecting the molecular marker SBDS.
7. A kit, characterized in that: The kit comprises the substance for detecting the molecular marker SBDS according to any one of claims 2 to 4, and is used for detecting the molecular marker SBDS or for diagnosis, auxiliary diagnosis, screening, auxiliary screening or prognosis evaluation of hepatocellular carcinoma.
8. A method for detecting the molecular marker SBDS, characterized in that: The method comprises using the primer pair described in claim 5 or the kit described in claim 7 to detect the sample to be tested.
9. The method according to claim 8, characterized in that The method comprises the following steps: A. Extract RNA from the sample to be tested; B. reverse transcribing the RNA into cDNA; C. Using the cDNA as a template, a PCR reaction is performed using the primer pair described in claim 5.
10. Any of the following uses of an agent or drug for overexpressing the molecular marker SBDS:
1. Use in the preparation of a drug for inhibiting the migration or metastasis of hepatocellular carcinoma cells; II. Application in the preparation of drugs for treating or preventing hepatocellular carcinoma.
